212 related articles for article (PubMed ID: 11028939)
1. Deformation behaviors of tolbutamide, hydroxypropyl-beta-cyclodextrin, and their dispersions.
Suihko E; Poso A; Korhonen O; Gynther J; Ketolainen J; Paronen P
Pharm Res; 2000 Aug; 17(8):942-8. PubMed ID: 11028939
[TBL] [Abstract][Full Text] [Related]
2. Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-beta-cyclodextrin.
Suihko E; Korhonen O; Järvinen T; Ketolainen J; Jarho P; Laine E; Paronen P
Int J Pharm; 2001 Mar; 215(1-2):137-45. PubMed ID: 11250099
[TBL] [Abstract][Full Text] [Related]
3. Molecular modelling and 1H-NMR: ultimate tools for the investigation of tolbutamide: beta-cyclodextrin and tolbutamide: hydroxypropyl-beta-cyclodextrin complexes.
Veiga FJ; Fernandes CM; Carvalho RA; Geraldes CF
Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1251-6. PubMed ID: 11605649
[TBL] [Abstract][Full Text] [Related]
4. Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-alpha- and -beta-cyclodextrins.
Kimura K; Hirayama F; Arima H; Uekama K
Pharm Res; 1999 Nov; 16(11):1729-34. PubMed ID: 10571279
[TBL] [Abstract][Full Text] [Related]
5. Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-beta-cyclodextrin complex.
Kimura K; Hirayama F; Arima H; Uekama K
Chem Pharm Bull (Tokyo); 2000 May; 48(5):646-50. PubMed ID: 10823700
[TBL] [Abstract][Full Text] [Related]
6. Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems.
Veiga F; Fernandes C; Maincent P
Drug Dev Ind Pharm; 2001 Jul; 27(6):523-32. PubMed ID: 11548859
[TBL] [Abstract][Full Text] [Related]
7. Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes.
Veiga F; Fernandes C; Teixeira F
Int J Pharm; 2000 Jul; 202(1-2):165-71. PubMed ID: 10915940
[TBL] [Abstract][Full Text] [Related]
8. Study of tolbutamide-hydroxypropyl-gamma-cyclodextrin interaction in solution and solid state.
Veiga MD; Ahsan F
Chem Pharm Bull (Tokyo); 2000 Jun; 48(6):793-7. PubMed ID: 10866138
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent densification behaviour of cyclodextrins.
Muñoz-Ruiz A; Paronen P
J Pharm Pharmacol; 1996 Aug; 48(8):790-7. PubMed ID: 8887726
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the complexes of furosemide with 2-hydroxypropyl-beta-cyclodextrin and sulfobutyl ether-7-beta-cyclodextrin.
Spamer E; Müller DG; Wessels PL; Venter JP
Eur J Pharm Sci; 2002 Sep; 16(4-5):247-53. PubMed ID: 12208454
[TBL] [Abstract][Full Text] [Related]
11. Complexation of zolpidem with 2-hydroxypropyl-beta-, methyl-beta-, and 2-hydroxypropyl-gamma-cyclodextrin: effect on aqueous solubility, dissolution rate, and ataxic activity in rat.
Trapani G; Latrofa A; Franco M; Pantaleo MR; Sanna E; Massa F; Tuveri F; Liso G
J Pharm Sci; 2000 Nov; 89(11):1443-51. PubMed ID: 11015689
[TBL] [Abstract][Full Text] [Related]
12. Fast dissolving cyclodextrin complex of piroxicam in solid dispersion part I: influence of β-CD and HPβ-CD on the dissolution rate of piroxicam.
Bouchal F; Skiba M; Chaffai N; Hallouard F; Fatmi S; Lahiani-Skiba M
Int J Pharm; 2015 Jan; 478(2):625-32. PubMed ID: 25522828
[TBL] [Abstract][Full Text] [Related]
13. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
Sherje AP; Kulkarni V; Murahari M; Nayak UY; Bhat P; Suvarna V; Dravyakar B
Mol Pharm; 2017 Apr; 14(4):1231-1242. PubMed ID: 28248111
[TBL] [Abstract][Full Text] [Related]
14. New injectable melphalan formulations utilizing (SBE)(7m)-beta-CD or HP-beta-CD.
Ma DQ; Rajewski RA; Stella VJ
Int J Pharm; 1999 Nov; 189(2):227-34. PubMed ID: 10536251
[TBL] [Abstract][Full Text] [Related]
15. The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-beta-cyclodextrin.
Gladys G; Claudia G; Marcela L
Eur J Pharm Sci; 2003 Nov; 20(3):285-93. PubMed ID: 14592694
[TBL] [Abstract][Full Text] [Related]
16. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
17. Spray-dried mucoadhesive microparticles based on S-protected thiolated hydroxypropyl-β-cyclodextrin for budesonide nasal delivery.
Racaniello GF; Laquintana V; Summonte S; Lopedota A; Cutrignelli A; Lopalco A; Franco M; Bernkop-Schnürch A; Denora N
Int J Pharm; 2021 Jun; 603():120728. PubMed ID: 34029665
[TBL] [Abstract][Full Text] [Related]
18. Particle characterization of poorly water-soluble drugs using a spray freeze drying technique.
Kondo M; Niwa T; Okamoto H; Danjo K
Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):657-62. PubMed ID: 19571408
[TBL] [Abstract][Full Text] [Related]
19. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects.
Lima BDS; Campos CA; da Silva Santos ACR; Santos VCN; Trindade GDGG; Shanmugam S; Pereira EWM; Marreto RN; Duarte MC; Almeida JRGDS; Quintans JSS; Quintans LJ; Araújo AAS
Food Chem Toxicol; 2019 Apr; 126():15-24. PubMed ID: 30738132
[TBL] [Abstract][Full Text] [Related]
20. Comparative muscle irritation and pharmacokinetics of florfenicol-hydroxypropyl-β-cyclodextrin inclusion complex freeze-dried powder injection and florfenicol commercial injection in beagle dogs.
Fan G; Zhang L; Shen Y; Shu G; Yuan Z; Lin J; Zhang W; Peng G; Zhong Z; Yin L; Fu H
Sci Rep; 2019 Nov; 9(1):16739. PubMed ID: 31723173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
